Business Wire

IL-DURAVANT

22.2.2021 13:02:06 CET | Business Wire | Press release

Share
Duravant Acquires Votech, European-based Bagging Automation Equipment Provider

Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced the acquisition of Votech GS B.V. (“Votech”), a leading manufacturer of bag filling machines, palletizer machines, stretch hood machines and pallet transport systems headquartered in Reusel, The Netherlands. Votech will join forces with Fischbein International, a Duravant Operating Company, to serve their global customer base.

The combination of Votech’s expertise in bag management and palletizing and Fischbein’s portfolio of bag sealing and sewing equipment creates a complementary fit between the two companies.

“There is a very complementary relationship between our two organizations,” said Olivier Hancotte, VP and General Manager of Fischbein. “We’re thrilled to work closely with the Votech team to create a broader product offering for both companies’ customers. Fischbein and Votech equipment will both be available through the Fischbein global sales team.”

This partnership brings together two global engineered equipment leaders and extends Duravant’s ability to serve customers and partners in over 190 countries worldwide across multiple sectors including agriculture, industrials, fruit and vegetables, ingredients, pet food and more.

“We’re excited to be a part of the Duravant group of world-class brands and automation solutions,” said Rolf Michiels, Director of Project Sales. “Aligning with the Fischbein team to better serve our customers through a united and collaborative strategy is an exciting prospect for us. Duravant’s lifecycle management via the company’s SupportPro services also gives our customers broader access to value-added solutions that will help their operations achieve their productivity and efficiency goals.”

The Votech brand of packaging machinery has been a competitive force in filling and bag management for over a decade. Votech’s deep engineering and development capabilities allow for the custom design of complete automated solutions from the filling of a bag, to the internal pallet transport to the warehouse. Recognized for superior engineering, package control and local field service support, Votech has proven success delivering packaging solutions for free-flowing and powders applications.

“Our partnership with Duravant opens the path for Votech’s geographic expansion and growth in Europe, the Middle-East, Africa and North America,” adds Pierre Dierckx, Director of Operations. “We’re thrilled to also collaborate with nVenia, Duravant’s US-based operating company serving customers across a wide array of industrial end markets and consumer packaged goods.” The Votech solution set for powders applications is highly complementary with the nVenia product range across primary, secondary and end-of-line packaging.

About Duravant

Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales and service facilities throughout North America, Europe and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end process solutions for customers and partners through engineering and integration expertise, project management and operational excellence. With worldwide sales distribution and service networks, they provide immediate and lifetime aftermarket support to all the markets they serve in the food processing, packaging and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability and reliability. For more information, visit www.duravant.com .

About Votech

Headquartered in Reusel, The Netherlands, Votech specializes in developing bag filling and palletizer machines, stretch hood machines and transport systems. The Votech brand has been recognized for providing complete packaging lines from the filling of a bag, through to the internal pallet transport to the warehouse. The entire Votech equipment portfolio is available through Fischbein, a Duravant Company. For more information, visit www.votechbv.co.uk .

About Fischbein

Fischbein designs and manufactures bag packaging equipment and complete systems. For over 100 years, Fischbein has been the leader in sewing and sealing systems by delivering highly engineered, robust and dependable solutions. Serving customers worldwide in agriculture, animal feed, seed, pet food, chemical, mineral, milling, food, building material, medical and pharmaceutical industries, Fischbein has a full range of sealing, filling, weighing, handling, and palletizing equipment that is sold and serviced in more than 190 countries. Fischbein is a Duravant Company. For more information, visit www.fischbein.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye